Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
Kayser, Sabine (Heidelberg University Hospital (Alemanya))
Rahmé, Ramy (Université Paris Diderot)
Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer)
Ghiaur, Gabriel (Johns Hopkins University)
Thomas, Xavier (Centre Hospitalier Lyon-Sud. Hospices Civils de Lyon)
Sobas, Marta (Wroclaw Medical University)
Guerci-Bresler, Agnes (Nancy University Hospital)
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau)
Pigneux, Arnaud (Bordeaux University Hospital (França))
Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià))
Raffoux, Emmanuel (Université Paris Diderot. Hôpital Saint Louis)
Tormo, Mar (Hospital Clínic Universitari (València))
Vey, Norbert (Institut Paoli Calmette)
de la Serna, Javier (Hospital Universitario 12 de Octubre (Madrid))
Salamero, Olga (Hospital Universitari Vall d'Hebron)
Lengfelder, Eva (University Hospital Mannheim (Alemanya))
Levis, Mark (Johns Hopkins University)
Fenaux, Pierre (Université Paris Diderot. Hôpital Saint Louis)
Sanz, Miguel A.. (Centro de Investigación Biomédica en Red de Cáncer)
Platzbecker, Uwe (University Hospital Leipzig)
Schlenk, Richard F. (German Cancer Research Center and Heidelberg University Hospital)
Adès, Lionel (Université Paris Diderot)
Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73. 4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during consolidation (CTX/ATRA/ATO; n = 148), or with CTX/ATRA (n = 259). Median follow-up for overall survival (OS) was 4. 8 years. Complete remissions (CR) were achieved in 92% with ATO/ATRA and 82% with CTX/ATRA; induction death rates were 8% and 18%, respectively. For analysis of postremission outcomes we combined the ATO/ATRA and CTX/ATRA/ATO groups (ATO/ATRA ± CTX). Cumulative incidence of relapse (CIR) was significantly lower after ATO/ATRA ± CTX compared with CTX/ATRA (P < 0. 001). The same held true when restricting the analysis according to the treatment period after the year 2000. OS of patients in CR1 was not different between ATO/ATRA ± CTX compared with CTX/ATRA (P = 0. 20). High (>10 × 10 9 /l) white blood cell (WBC) counts at diagnosis were associated with higher CIR (P < 0. 001) compared with lower WBC in the CTX/ATRA group, but not in the ATO/ATRA ± CTX group (P = 0. 48). ATO, when added to ATRA or CTX/ATRA is feasible and effective in elderly patients for remission induction and consolidation, particularly in patients with high WBC at diagnosis.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Acute myeloid leukaemia ; Clinical genetics
Publicat a:	Leukemia, Vol. 34 (february 2020) , p. 2333-2341, ISSN 1476-5551

Erratum: https://ddd.uab.cat/record/250525
DOI: 10.1038/s41375-020-0758-4
PMID: 32076120

9 p, 621.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats